궤양 치료를 위한 약제학적 고체 분산체 제제 및 이의 제조방법
    22.
    发明公开
    궤양 치료를 위한 약제학적 고체 분산체 제제 및 이의 제조방법 有权
    用于治疗尿液的药物固体分散配方及其制备方法

    公开(公告)号:KR1020130134353A

    公开(公告)日:2013-12-10

    申请号:KR1020120057807

    申请日:2012-05-30

    CPC classification number: A61K9/143 A61K9/146 A61K31/4704 Y10S514/925

    Abstract: The present invention relates to a pharmaceutical solid dispersion formulation for treatment of an ulcer and a preparing method thereof and, more particularly, to a pharmaceutical solid dispersion formulation for treatment of ulcer, capable of improving drug solubility and bioavailability, containing rebamipide, a water-soluble polymer, and a non-ionic surfactant. Thus, the present invention provides a method for preparing a solid dispersion formulation having improved drug solubility and bioavailability, so that the pharmaceutical formulation can have improved efficacy and thus be used for effective treatment of ulcer. [Reference numerals] (AA) Ulcer area(mm^2);(BB) Control group

    Abstract translation: 本发明涉及用于治疗溃疡的药物固体分散体制剂及其制备方法,更具体地涉及能够改善药物溶解度和生物利用度的药物固体分散体制剂,其可用于治疗溃疡,其包含瑞巴派特, 可溶性聚合物和非离子表面活性剂。 因此,本发明提供了制备具有改进的药物溶解度和生物利用度的固体分散体制剂的方法,使得药物制剂可以具有改善的功效,因此用于有效治疗溃疡。 (AA)溃疡面积(mm ^ 2);(BB)对照组

    서방성 미립자 조성물 및 이의 제조 방법
    23.
    发明公开
    서방성 미립자 조성물 및 이의 제조 방법 无效
    持续释放微生物组合物及其生产方法

    公开(公告)号:KR1020130003602A

    公开(公告)日:2013-01-09

    申请号:KR1020110065045

    申请日:2011-06-30

    Abstract: PURPOSE: A sustained release microparticle composition containing tamsulosin, ethyl cellulose, and enteric polymer is provided to ensure sustained release and enteric properties. CONSTITUTION: A sustained release microparticle composition contains tamsulosin or a pharmaceutically acceptable salt thereof, ethyl cellulose, and enteric polymers. The enteric polymers are hydroxypropylmethyl cellulosephthalate, hydroxypropylmethyl cellulose acetatesuccinate, or methacrylic acid-acrylic acid ethyl copolymers. [Reference numerals] (AA) Released amount of medicine; (BB) Time(minutes); (CC) Comparative embodiment 4; (DD) Comparative embodiment 5; (EE) Embodiment 1; (FF) Embodiment 2; (GG) Embodiment 3

    Abstract translation: 目的:提供含有坦索罗辛,乙基纤维素和肠溶性聚合物的持续释放微粒组合物,以确保持续释放和肠溶性。 构成:缓释微粒组合物含有坦索罗辛或其药学上可接受的盐,乙基纤维素和肠溶聚合物。 肠溶性聚合物是羟丙基甲基纤维素邻苯二甲酸酯,羟丙基甲基纤维素乙酸丁二酸酯或甲基丙烯酸 - 丙烯酸乙基共聚物。 (附图标记)(AA)药物释放量; (BB)时间(分钟); (CC)比较实施例4; (DD)比较实施例5; (EE)实施例1; (FF)实施例2; (GG)实施例3

Patent Agency Ranking